STI571: A paradigm of new agents for cancer therapeutics Academic Article Article uri icon


MeSH Major

  • Antigens, CD34
  • Antigens, CD38
  • Antineoplastic Agents
  • Chromosome Aberrations
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases


  • STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose selection, optimizing therapy, and predicting response, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies are explored.

publication date

  • January 2002



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1200/JCO.20.1.325

PubMed ID

  • 11773186

Additional Document Info

start page

  • 325

end page

  • 34


  • 20


  • 1